Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2015 August;63(4) > Minerva Cardioangiologica 2015 August;63(4):343-57

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Per citare questo articolo

 

REVIEW   

Minerva Cardioangiologica 2015 August;63(4):343-57

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

Next generation TAVI with the Lotus Valve System: a repositionable and fully retrievable transcatheter aortic valve prosthesis

Murdoch D. 1, 2, Shaw E. 1, 3, Raffel O. C. 1, 2, Walters D. L. 1, 2

1 Heart and Lung Institute, The Prince Charles Hospital, Brisbane, Australia; 2 School of Medicine, University of Queensland, Brisbane, Australia; 3 School of Medicine, The University of Sydney, Sydney, Australia


PDF


Transcatheter aortic valve implantation (TAVI) is the new standard of care for selected patients with severe symptomatic aortic stenosis who are at high risk for surgical aortic valve replacement (AVR), or are inoperable. Multicentre randomised controlled trials have demonstrated equivalent or superior clinical outcomes for TAVI compared to AVR in carefully selected patient cohorts. A number of important limitations were observed with early generation TAVI valves and their delivery systems, and rapid evolution of the technology continues. The Lotus Valve System aims to address a number of these limitations – it is repositionable and retrievable, and has an adaptive seal to prevent paravalvular aortic regurgitation. Early clinical outcomes for the Lotus Valve System have recently been published with promising results in terms of paravalvular regurgitation and repositionability.

inizio pagina